Investing into early-phase biomedical companies is associated with high risks. Data quality, important for future success of drug discovery programs, is often not evaluated because conventional due diligence procedures rarely involve research bias analysis (e.g. study design, data analysis, selective data presentation). In addition, investments focus on unprecedented MOAs, which are per se at higher risk.
|Challenges||Our Value Proposition|
|Too many projects to review||Screen more projects in shorter time|
|No tools to rationalise fast decision-making on early projects||Applying PAASPort at any stage of a preclinical project to facilitate decisions based on data quality|
|Need to make investment to learn whether a project is based on high-quality data||Learn about critical quality aspects before investing in projects|
Contact as for a detailed offer on how we could support you in excluding projects with low chances on translatability.